ProZyme, Inc. en BiOptic, Inc. tekenen licentieovereenkomst voor ontwikkeling Gly-Q
HAYWARD, Calif.–(BUSINESS WIRE)– ProZyme, Inc., producent van bioreactanten voor glycobiologie, en het Taiwanese bedrijf BiOptic Inc., fabrikant van instrumenten voor DNA-analyse, maken bekend dat ze een samenwerkingsovereenkomst hebben gesloten over de ontwikkeling en vermarkting van een geïntegreerd systeem voor glyco-analyse. Gly-Q, zoals het systeem heet, zorgt voor een hoge doorvoer en is gebruiksvriendelijk. Dankzij de samenwerking vergroot ProZyme zijn portfolio van glycobiologieproducten. Daarnaast profiteert het bedrijf van BiOptics aanbod van robuuste en accurate instrumenten voor capillaire elektroferese (CGE).
Krachtens de licentieovereenkomst gebruikt ProZyme het automatische CGE-platform van BiOptic met gepatenteerde fluo-detectie en vervangbare vullingen, dat is ontwikkeld voor een snelle detectie en scheiding van gelabelde glycanen.
ProZyme, Inc. and BiOptic, Inc. Sign Licensing Agreement to Develop Gly-Q System for Glycan Analysis
HAYWARD, Calif.–(BUSINESS WIRE)– ProZyme, Inc., manufacturer of bioreagents for glycobiology, and BiOptic Inc. of Taiwan, manufacturer of instruments for DNA analysis by capillary gel electrophoresis (CGE), today announce an agreement to collaborate on the development and commercialization of an integrated system (Gly-Q™) for high-throughput, user-friendly glycoanalysis. The Gly-Q collaboration will extend ProZyme’s portfolio of glycobiology products, and will leverage BiOptic’s line of rugged and accurate CGE instruments.
Under the terms of the OEM/ODM licensing agreement, ProZyme will utilize BiOptic’s automated CGE platform with patented fluorescence detection and replaceable gel-cartridge design for rapid separation and detection of labeled glycans. At the front end of the Gly-Q system, enzymatically-released and fluorescently-labeled glycans will be prepared using ProZyme chemistry prior to glycan separation using the automated CGE instrument. Data analysis will be simplified by the use of customized software and ProZyme N-glycan reference standards. The combined Gly-Q system for N-glycan sample preparation, separation and analysis will be exclusively marketed by ProZyme worldwide.
Protein glycosylation is a post-translational modification that can influence the efficacy and safety of therapeutic proteins such as monoclonal antibodies. Traditional methods for glycan analysis involve slow and labor-intensive steps for sample preparation, glycan separation and data analysis. To this end, ProZyme and BiOptic plan to introduce the Gly-Q system to enable high-throughput and accessible glycoanalysis for use in applications such as biotherapeutic cell line development.
ProZyme will present preliminary data on use of the Gly-Q system for N-glycan analysis of biotherapeutics in a poster presentation at the California Separation Science Society (CASSS) CE Pharm meeting held in Brooklyn, NY, September 20-24, 2015. The commercialized ProZyme Gly-Q glycoanalysis workflow is expected to be available in early 2016.
About ProZyme
ProZyme, Inc. was founded in 1990 with a vision of establishing a high-quality, value-added and customer-driven biochemical reagent company. We are proud, 25 years on, to provide the highest level of products, services and support to customers at biotechnology, biopharmaceutical and academic institutions worldwide. ProZyme’s flagship product line is our glycobiology portfolio, alongside streptavidin, phycobiliprotein and conjugate offerings, and we perform custom analytical services in collaboration with our customers. ProZyme maintains a commitment to develop, release and support products in the exciting and rapidly-expanding area of glycobiology.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150916006834/en/
Contacts
ProZyme, Inc.
Dr. Aled Jones, 510-638-6900
Senior Product Manager
info@prozyme.com
www.prozyme.com
3832 Bay Center Place
Hayward, CA 94545, USA